# US 2010/0249134 A1 · Use of Beta-Adrenoceptor Antagonists for the Manufacture of a Medicament for the Treatment of Disorders of the Outer Retina

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0249134 A1
- Document ID: US20100249134A1
- Status: Published application
- Kind: A1
- Application number: 12/796,942
- Filed: 2010-06-09
- Published: 2010-09-30
- Earliest claimed: 1999-11-30
- Assignees: Alcon Inc.
- Inventors: Robert J. Collier, Jr.; Louis DeSantis, JR.; Michael A. Kapin
- Web page: https://patentgrep.com/patent/US20100249134A1

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for treating disorders of the outer retina with β-adrenoceptor antagonists are disclosed.

## Claims

### Claim 1

A method of inducing endogenous production of neurotrophic factors in an eye, comprising delivering an ophthalmic composition comprising a β-adrenoceptor antagonist to the eye.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ophthalmic composition comprises from 0.001% to 5% w/v of the β-adrenoceptor antagonist in a pharmaceutical acceptable carrier.

### Claim 3 (depends on 2)

The method of claim 2, wherein the concentration of the β-adrenoceptor antagonist is from 0.01% to 2% w/v.

### Claim 4 (depends on 3)

The method of claim 3, wherein the concentration of the β-adrenoceptor antagonist is from 0.25% to 0.75% w/v.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ophthalmic composition further comprises poly(styrene divinylbenzene) Sulfonic Acid.

### Claim 6 (depends on 1)

The method of claim 1, wherein the neurotrophic factors include CNTF and bFGF.

### Claim 7 (depends on 1)

The method of claim 1 wherein the β-adrenoceptor antagonist is selected from the group consisting of: betaxolol (R or S or racemic), timolol, carteolol, levobunolol, metipranolol, befunolol, propranolol, metoprolol, atenolol, pendolol, and pinbutolol.

### Claim 8 (depends on 7)

The method of claim 7 wherein the β-adrenoceptor antagonist is betaxolol or its R or S isomer.